Purpose: Long-axial field-of-view PET scanners capture multi-organ tracer distribution with high sensitivity, enabling lower dose dynamic protocols and dual-tracer imaging for comprehensive disease characterization. However, reducing dose may compromise data quality and time-activity curve (TAC) fitting, leading to higher bias in kinetic parameters. Parametric imaging poses further challenges due to noise amplification in voxel-based modelling. We explore the potential of deep learning denoising (DL-DN) to improve quantification for low-dose dynamic PET.

Methods: Using 16 [F]FDG PET studies from the PennPET Explorer, we trained a DL framework on 10-min images from late-phase uptake (static data) that were sub-sampled from 1/2 to 1/300 of the counts. This model was used to denoise early-to-late dynamic frame images. Its impact on quantification was evaluated using compartmental modelling and voxel-based graphical analysis for parametric imaging for single- and dual-tracer dynamic studies with [F]FDG and [F]FGln at original (injected) and reduced (sub-sampled) doses. Quantification differences were evaluated for the area under the curve of TACs, K for [F]FDG and V for [F]FGln, and parametric images.

Results: DL-DN consistently improved image quality across all dynamic frames, systematically enhancing TAC consistency and reducing tissue-dependent bias and variability in K and V down to 40 MBq doses. DL-DN preserved tumor heterogeneity in Logan V images and delineation of high-flux regions in Patlak K maps. In a /[F]FDG dual-tracer study, bias trends aligned with single-tracer results but showed reduced accuracy for [¹⁸F]FGln in breast lesions at very low doses (4 MBq).

Conclusion: This study demonstrates that applying DL-DN trained on static [F]FDG PET images to dynamic [F]FDG and [F]FGln PET can permit significantly reduced doses, preserving accurate FDG K and FGln V measurements, and enhancing parametric image quality. DL-DN shows promise for improving dynamic PET quantification at reduced doses, including novel dual-tracer studies.

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00259-025-07182-6DOI Listing

Publication Analysis

Top Keywords

[f]fdg [f]fgln
12
deep learning
8
learning denoising
8
dynamic
8
low-dose dynamic
8
dynamic pet
8
single- dual-tracer
8
dual-tracer imaging
8
parametric imaging
8
[f]fdg pet
8

Similar Publications

Purpose: Long-axial field-of-view PET scanners capture multi-organ tracer distribution with high sensitivity, enabling lower dose dynamic protocols and dual-tracer imaging for comprehensive disease characterization. However, reducing dose may compromise data quality and time-activity curve (TAC) fitting, leading to higher bias in kinetic parameters. Parametric imaging poses further challenges due to noise amplification in voxel-based modelling.

View Article and Find Full Text PDF

Evaluation of (2S,4S)-4-[F]FEBGln as a Positron Emission Tomography Tracer for Tumor Imaging.

Mol Pharm

October 2023

Beijing Institute of Brain Disorders, Laboratory of Brain Disorders, Ministry of Science and Technology, Collaborative Innovation Center for Brain Disorders, Capital Medical University, Beijing 100069, China.

Glutamine metabolism-related tracers have the potential to visualize numerous tumors because glutamine is the second largest source of energy for tumors. (2S,4S)-4-[F]FEBGln was designed by introducing [F]fluoroethoxy benzyl on carbon-4 of glutamine. The aim of this study was to investigate the pharmacokinetic properties and tumor positron emission tomography (PET) imaging characteristics of (2S,4S)-4-[F]FEBGln in detail.

View Article and Find Full Text PDF

Increased glutamine metabolism by macrophages is associated with development of atherosclerotic lesions. Positron emission tomography/computed tomography (PET/CT) with a glutamine analog (2S,4)-4-F-fluoroglutamine (F-FGln) allows quantification of glutamine consumption . Here, we investigated uptake of F-FGln by atherosclerotic lesions in mice and compared the results with those obtained using the glucose analog 2-deoxy-2-F-fluoro--glucose (F-FDG).

View Article and Find Full Text PDF

The high glycolytic activity of multiple myeloma (MM) cells is the rationale for use of Positron Emission Tomography (PET) with F-fluorodeoxyglucose ([F]FDG) to detect both bone marrow (BM) and extramedullary disease. However, new tracers are actively searched because [F]FDG-PET has some limitations and there is a portion of MM patients who are negative. Glutamine (Gln) addiction has been recently described as a typical metabolic feature of MM cells.

View Article and Find Full Text PDF

Purpose: The three positron emission tomography (PET) imaging compounds: (2,4)-4-[F]Fluoroglutamine ([F]FGln), -[methyl-C]Methionine ([C]Met), and 2-deoxy-2-[F]fluoro--glucose ([F]FDG) were investigated to contrast their ability to image orthotopic BT4C gliomas in BDIX rats. Two separate small animal imaging systems were compared for their tumor detection potential. Dynamic acquisition of [F]FGln was evaluated with multiple pharmacokinetic models for future quantitative comparison.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!